Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Diagnostic validity of colchicine in patients with Familial Mediterranean fever.
[familial mediterranean fever]
Although
response
to
colchicine
has
been
proposed
as
one
of
the
diagnostic
criteria
in
patients
with
Familial
Mediterranean
fever
(
FMF
)
,
the
validity
of
this
response
has
not
been
validated
.
The
aim
of
this
study
was
to
assess
the
efficacy
of
the
response
to
colchicine
and
to
evaluate
the
extent
of
the
effect
of
placebo
.
A
double
-blind
randomized
placebo-controlled
trial
with
a
cross-over
design
was
conducted
.
The
frequency
of
FMF
attacks
,
the
disease
score
,
physical
examination
,
and
acute
phase
reactants
were
assessed
at
0
,
3
,
and
6
Â
months
.
Blood
samples
were
collected
for
complete
blood
count
(
CBC
)
,
erythrocyte
sedimentation
rate
(
ESR
)
,
levels
of
serum
C-
reactive
protein
(
CRP
)
and
serum
amyloid
A
(
SAA
)
,
and
MEFV
mutation
analysis
in
79
patients
with
a
preliminary
diagnosis
of
FMF
.
Patients
were
randomly
allocated
to
receive
either
drug
A
or
drug
B
in
a
double
-blind
fashion
.
The
designated
drug
was
switched
at
3
Â
months
.
Patients
taking
colchicine
had
less
frequent
FMF
attacks
(
median
0
)
and
lower
FMF
disease
score
(
median
0
)
when
compared
to
those
on
placebo
(
median
1
and
3
,
respectively
)
(
p
 
=
 
0
.
002
and
p
 
=
 
0
.
007
,
respectively
)
.
In
genetically
confirmed
FMF
patients
,
median
attack
number
and
median
disease
score
was
0
under
colchicine
treatment
,
whereas
these
parameters
were
significantly
higher
in
the
placebo
group
(
median
2
and
8
,
respectively
)
(
p
 
=
 
0
.
007
and
p
 
=
 
0
.
02
,
respectively
)
suggesting
that
colchicine
is
more
effective
than
placebo
in
reducing
attacks
and
disease
score
.
Positive
and
negative
predictive
values
were
70
.
2
and
37
.
5
Â
%
,
respectively
.
During
the
placebo
period
,
patients
had
less
FMF
attacks
when
compared
to
that
of
the
pre-study
period
(
median
2
vs
6
,
respectively
)
(
p
 
<
 
0
.
001
)
.
The
high
false
positive
rate
raises
concerns
for
considering
the
colchicine
response
test
as
diagnostic
for
FMF
.
The
role
of
placebo
on
the
attacks
of
periodic
fever
syndromes
needs
to
be
further
investigated
.
Diseases
Validation
Diseases presenting
"fever"
symptom
22q11.2 deletion syndrome
acute rheumatic fever
alexander disease
allergic bronchopulmonary aspergillosis
canavan disease
carcinoma of the gallbladder
child syndrome
congenital toxoplasmosis
cushing syndrome
cystinuria
dracunculiasis
erdheim-chester disease
esophageal adenocarcinoma
esophageal carcinoma
familial mediterranean fever
focal myositis
hodgkin lymphoma, classical
lamellar ichthyosis
legionellosis
locked-in syndrome
malignant atrophic papulosis
neonatal adrenoleukodystrophy
neuralgic amyotrophy
oculocutaneous albinism
papillon-lefèvre syndrome
pyomyositis
pyruvate dehydrogenase deficiency
scrub typhus
severe combined immunodeficiency
sneddon syndrome
systemic capillary leak syndrome
triple a syndrome
typhoid
waldenström macroglobulinemia
wolf-hirschhorn syndrome
This symptom has already been validated